惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

WordPress大学
WordPress大学
大猫的无限游戏
大猫的无限游戏
酷 壳 – CoolShell
酷 壳 – CoolShell
博客园 - 叶小钗
月光博客
月光博客
Last Week in AI
Last Week in AI
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
人人都是产品经理
人人都是产品经理
阮一峰的网络日志
阮一峰的网络日志
罗磊的独立博客
IT之家
IT之家
美团技术团队
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
Hugging Face - Blog
Hugging Face - Blog
博客园_首页
S
SegmentFault 最新的问题
宝玉的分享
宝玉的分享
博客园 - Franky
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
Jina AI
Jina AI
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
The Cloudflare Blog
博客园 - 司徒正美
爱范儿
爱范儿

Futurism

Chinese Government Dismisses Tech Billionaire Calls for an AI Slowdown as "Fear-Mongering" Sam Altman Now Trying to Gain Control of Electric Grid Dyson's New AI Toothbrush Conducts Video Surveillance on the Inside of Your Mouth Man Pretends to Hallucinate in Job Interview With an AI Bot, Causing It to Go Haywire Even Babies Are Still Way Better at Learning Than AI Models Farmer Horrified as AI Gives Bad Advice That Kills 25 Acres of Crops Better Hope You Don't Need an Ambulance in New Orleans, Because the City's 911 Operators Are Now AI Amazon Is Gutting Its AI Division After Sustained Failure Suspicion Grows About OpenAI's Tale About Its Rogue Hacker AI Frontier AI Is Faceplanting at Real-World Workplace Tasks A Chinese AI Model Just Shot to Number One on the Charts, Sending Shockwaves Through the American Tech Industry Tech Bros Puzzled by Why AI Hasn't "Massively Disrupted" Books Yet AI Companies Are Learning an Ironic Lesson as the People They Pay to Improve Their Chatbots Are Just Feeding AI Slop Into Them Sports Journalists Asked Microsoft’s Copilot to Predict World Cup Matches, and the Results May Surprise You Researchers Put AI Models in Charge of Analyzing Sports, and They Choked Spectacularly Fans Aghast as New York Jets Say They’re Switching to AI Companies That Adopted AI Agents Alarmed to Discover They’re Botching Incredibly Important Tasks Hackers Find That Inaudible Sounds Hidden in Podcasts or Random Videos Can Hijack Your AI Voice Chatbot Democrats’ 2024 Election Autopsy Shows Signs of Sloppy AI Generation Being a Crappy Boss to AI Chatbots Pushes Them Toward Spouting Marxist Rhetoric and Organizing With Their Compatriots, Researchers Find Amazon Employees Forced to Hit Quotas on AI Use, Immediately Start Using it for Everything Except Work These Smart Glasses That Show Captions of What Everyone’s Saying Without a Creepy Spy Camera Actually Seem Pretty Awesome AI Appears to Be Trapping Certain Job Applicants in a Limbo Where They Never Get an Interview for “Reasons” That Are Completely Unfair The AI Industry Is Secretly Powered by Homeless People ChatGPT Is Saying VWeird Things in Chinese America Trembles as Transportation Secretary Announces Plans for Air Traffic Controllers to Lean on AI Tools Today Is the Day Anthropic Promised That Fully Autonomous Employees Would Be Tearing Through the Business World China Is Starting to Pull Ahead of US in AI Race Berklee College of Music Students Furious That It’s Offering an AI “Songwriting” Class Usually, Young People Embrace New Technology. Gen Z’s Attitude Toward AI Should Worry the Entire Tech Industry
Man Announces That He Has Synthesized a New Schizophrenia...
Joe Wilkins · 2026-09-10 · via Futurism

Screenshots of a new drug that was purportedly devised in a man's garage.

Douglas Yao via X

These days, large language models are pushing the line between schizophrenic break and reality closer than ever before.

In a wild new post that’s going viral on X-formerly-Twitter, an enterprising young biochemist named Douglas Yao showcased a new drug he’s been developing with the aid of ChatGPT. He’s not employed by any pharma company, and his drug lab is setup on a couple folding tables in his garage.

Specifically, Yao enthuses about a new drug he calls “PAC-3310,” which he says is meant to treat schizophrenia. “It was designed by ChatGPT,” Yao explains, “and I synthesized it in a chemistry lab I built in my garage.”

The result is a small vial of yellow powder — the first sample of 3310, apparently — which Yao says is modeled after the recently-authorized antipsychotic Cobenfy, “but improved.”

This vial contains a new drug called PAC-3310. It was designed by ChatGPT, and I synthesized it in a chemistry lab I built in my garage.

PAC-3310 is a new selective M4 muscarinic receptor agonist for treating schizophrenia – similar to the recent breakthrough drug Cobenfry, but… pic.twitter.com/o7z6iLR50T

— Douglas Yao (@DouglasYaoDY) September 8, 2026

On his GitHub page, Yao boasts that he’s used AI to “design several thousand new small molecule drugs” over the past year, including a “new Alzheimer’s drug,” which he’s developing in addition to the schizophrenia treatment.

“I then taught myself synthetic chemistry, built a chem lab in my garage, and synthesized a hundred of them,” he continued. “I’m now testing these compounds in cell lines and mice.”

But whatever the one-man pharma lab hopes to accomplish is difficult to say. Yao references the fact that “drug developers typically spend tens of millions of dollars generating pre-clinical efficacy evidence for a new drug,” saying that “my approach can do this at 1/1000 the cost.” This seems to suggest dreams of someday manufacturing the various drugs on a massive scale for human consumption — a process that would take years of grueling and expensive work for a well-resourced drug lab, let alone a solo entrepreneur using a box fan as a fume hood.

For instance, to even approach the Food and Drug Administration’s “New Drug Application” — itself a costly 12-month process requiring inspection of the facility where the drug will be manufactured — one first has to conduct rounds of preclinical testing followed by three phases of clinical trials. Forget “tens of millions,” as Yao mentions; this is a process that can easily cost several billion.

Even then success is far from guaranteed, as only 13.8 percent of drugs that enter clinical trials go on to obtain full approval from the FDA.

While Yao might have been right at home in the free-wheeling research landscape of the 1970s, we no longer live in a world where a mad genius can synthesize hundreds of new drugs a year from a private lab. For one thing, the regulatory environment is much more demanding, as outlined above, to say nothing of the fact that all the low-hanging fruit has been picked from the vine decades ago.

When it comes to Yao’s ChatGPT-generated Alzheimer’s treatment, the landscape is particularly fraught. As one 2019 study found, no new drug has been approved to treat Alzheimer’s since 2003, and not for a lack of trying: as the study notes, over 200 proposed substances meant to treat the disease have either failed in clinical trials or been abandoned by their creators.

The graveyard of failed Alzheimer’s treatments is so vast that the renowned organic chemist Derek Lowe has built a blog on drug discovery which routinely features after-action reports on failed substances designed to treat the neurodegenerative disease. Simply put, to think that ChatGPT alone is enough to overcome these scientific and institutional hurdles is delusional.

Replies to Yao’s post were quick to point out the irony here, of using ChatGPT — which is well-known for leading vulnerable users down dangerous breaks from reality — to synthesize drugs to treat cognitive diseases like Alzheimer’s and schizophrenia.

“Hello schizophrenic, take this medicine that chatgpt made for you,” one poster quipped on X.

Another replied that “believing you single-handedly cured schizophrenia on a commercial laundry folding table in a garage is, ironically, a classic symptom of schizophrenia.”

More on ChatGPT: Man Obliterated When Court Obtains His ChatGPT Transcripts